MUSTANG BIO, INC. (MBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US62818Q3020
MUSTANG BIO, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -2.43 m USD |
| EBIT | -1.89 m USD |
| Net income | -1.92 m USD |
| Diluted EPS – continuing operations | -0.39 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MUSTANG BIO, INC.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
More stocks
- Onfolio Holdings, Inc (ONFO)
- Trinity Place Holdings Inc. (TPHS)
- Peraso Inc. (PRSO)
- Brownie's Marine Group, Inc (BWMG)
- CIMG Inc. (CIMG)
- Propanc Biopharma, Inc. (PPCB)
- Nexalin Technology, Inc. (NXL)
- Sunshine Biopharma Inc. (SBFM)
- NEXGEL, INC. (NXGL)
- Circle Energy, Inc./NV (CRCE)
- ALTEX INDUSTRIES INC (ALTX)
- Accustem Sciences Inc. (ACUT)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.